{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,20]],"date-time":"2026-05-20T22:12:20Z","timestamp":1779315140250,"version":"3.51.4"},"reference-count":50,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T00:00:00Z","timestamp":1659916800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"DOI":"10.13039\/100010877","name":"ViiV Healthcare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100010877","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["onlinelibrary.wiley.com"],"crossmark-restriction":true},"short-container-title":["HIV Medicine"],"published-print":{"date-parts":[[2023,3]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Objectives<\/jats:title><jats:p>A paradigm shift from three\u2010drug regimens to two\u2010drug regimens (2DRs) is currently taking place in real\u2010world clinical practice. This study aimed to describe the efficacy, durability, and tolerability of dolutegravir (DTG)\/lamivudine (3TC) and DTG\/rilpivirine (RPV) in a real\u2010world setting.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>This was a retrospective, observational, multicentre (ten centres in Belgium) study involving adult treatment\u2010na\u00efve and treatment\u2010experienced people living with HIV on DTG\/3TC or DTG\/RPV between 1 January 2019 and 30 September 2020. The primary endpoint was rate of virological suppression (VS; plasma HIV\u20101 viral load [VL] &lt;50 copies\/ml) using an on\u2010treatment analysis. Main secondary endpoints included the proportion of people that experienced loss of VS (LVS; defined as two consecutive HIV\u20101 VLs of &gt;200\u2009copies\/ml after initially achieving VS) and a resistance analysis at the time of LVS; rate, incidence, and reasons for discontinuation of treatment (stopping treatment or changing any component of the 2DR); and change in weight, along with the proportion of people reporting a &gt;10% weight gain. Ordinal logistic regression analysis examined associations between baseline variables and &gt;10% on\u2010treatment weight gain.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>Overall, 948 people were included, of whom 734 (77%) were on DTG\/3TC and 214 (23%) were on DTG\/RPV. Baseline characteristics included 54% aged\u2009\u226550\u2009years, 31% female, 31% Black sub\u2010Saharan African, 95% treatment\u2010experienced, and 8% with HIV\u20101 VL\u2009\u226550 copies\/ml. Through 48\u2009weeks, the rate of VS for the overall cohort was 98.3% (99.1% with 3TC; 96.2% with RPV). LVS was observed in 0.5% (<jats:italic>n<\/jats:italic>\u00a0=\u00a05) of the overall population (<jats:italic>n<\/jats:italic>\u00a0=\u00a01 [3TC group], <jats:italic>n<\/jats:italic>\u00a0=\u00a04 [RPV group]). There were 40 treatment discontinuations (4.2%, <jats:italic>n<\/jats:italic>\u00a0=\u00a027 [3TC group]; <jats:italic>n<\/jats:italic>\u00a0=\u00a013 [RPV group]), corresponding to an incidence of 4.7 per 100 patient\u2010years. The most common reason for discontinuation was an adverse event (1.4%), with neurotoxicity the most frequent (0.5%). Median on\u2010treatment weight gain at week 48 was 1\u00a0kg (interquartile range [IQR] \u22121\u20133) overall, 1\u00a0kg (IQR \u22121\u20133) in the 3TC group, and 2\u00a0kg (IQR 0\u20134) in the RPV group. A &gt;10% weight increase was observed in 6.3% of people. Regression analysis showed that being on a tenofovir disoproxil fumarate\u2010based regimen prior to 2DR initiation was the only variable associated with a &gt;10% increase in weight from baseline (odds ratio 3.48; 95% confidence interval 1.13\u201310.68; <jats:italic>p<\/jats:italic>\u00a0=\u00a00.038).<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>In this real\u2010world analysis, the 2DRs analysed were effective, durable, and safe for those who were treatment\u2010naive and treatment\u2010experienced. A slight increase in weight was associated with these regimens.<\/jats:p><\/jats:sec>","DOI":"10.1111\/hiv.13373","type":"journal-article","created":{"date-parts":[[2022,8,8]],"date-time":"2022-08-08T08:43:06Z","timestamp":1659948186000},"page":"267-278","update-policy":"https:\/\/doi.org\/10.1002\/crossmark_policy","source":"Crossref","is-referenced-by-count":19,"title":["Efficacy, durability, and tolerability of dolutegravir\/lamivudine and dolutegravir\/rilpivirine for the treatment of <scp>HIV<\/scp> in a real\u2010world setting in Belgium"],"prefix":"10.1111","volume":"24","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-1265-1500","authenticated-orcid":false,"given":"Rakan","family":"Nasreddine","sequence":"first","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jean Cyr","family":"Yombi","sequence":"additional","affiliation":[{"name":"Cliniques Universitaires Saint\u2010Luc  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-8192-1351","authenticated-orcid":false,"given":"Gilles","family":"Darcis","sequence":"additional","affiliation":[{"name":"Li\u00e8ge University Hospital  Li\u00e8ge Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric","family":"Florence","sequence":"additional","affiliation":[{"name":"Institute of Tropical Medicine  Antwerp Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sabine D.","family":"Allard","sequence":"additional","affiliation":[{"name":"Universitair Ziekenhuis Brussel  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marie\u2010Ang\u00e9lique","family":"De Scheerder","sequence":"additional","affiliation":[{"name":"Ghent University Hospital  Ghent Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sophie","family":"Henrard","sequence":"additional","affiliation":[{"name":"University Clinics of Brussels \u2013 Erasme Hospital  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"R\u00e9my","family":"Demeester","sequence":"additional","affiliation":[{"name":"University Hospital of Charleroi  Lodelinsart Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Peter","family":"Messiaen","sequence":"additional","affiliation":[{"name":"Jessa Hospital  Hasselt Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Nathalie","family":"Ausselet","sequence":"additional","affiliation":[{"name":"UCL University Hospital Namur\u2010Godinne  Yvoir Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Matthias","family":"Loeckx","sequence":"additional","affiliation":[{"name":"ViiV Healthcare  Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marc","family":"Delforge","sequence":"additional","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"St\u00e9phane","family":"De Wit","sequence":"additional","affiliation":[{"name":"Saint\u2010Pierre University Hospital  Brussels Belgium"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"name":"the Belgian Research on AIDS and HIV Consortium (BREACH)","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"311","published-online":{"date-parts":[[2022,8,8]]},"reference":[{"key":"e_1_2_10_2_1","unstructured":"Department of Health and Human Services.Panel on Antiretroviral Guidelines for Adults and Adolescents. Guidelines for the Use of Antiretroviral Agents in Adults and Adolescents with HIV. Accessed September 6 2021.https:\/\/clinicalinfo.hiv.gov\/sites\/default\/files\/guidelines\/documents\/AdultandAdolescentGL.pdf"},{"key":"e_1_2_10_3_1","unstructured":"European AIDS Clinical Society.Guidelines version 11 October 2021. Accessed November 2 2021.https:\/\/www.eacsociety.org\/files\/guidelines\u201010.1_finaljan2021_1.pdf"},{"key":"e_1_2_10_4_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2020.17025"},{"key":"e_1_2_10_5_1","unstructured":"World Health Organization.Updated recommendations on first\u2010line and second\u2010line antiretroviral regimens and post\u2010exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidance 2018. Accessed November 2 2021.https:\/\/www.who.int\/hiv\/pub\/guidelines\/ARV2018update\/en"},{"key":"e_1_2_10_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(18)32462-0"},{"key":"e_1_2_10_7_1","unstructured":"WykJV AjanaF BisshopF et al.Switching to DTG\/3TC fixed\u2010dose combination (FDC) is non\u2010inferior to continuing a TAF\u2010based regimen in maintaining virologic suppression through 48\u2009weeks (TANGO study Oral Presentation). Presented at the 10th International AIDS Society Conference on HIV Science July 2019 Mexico City Mexico."},{"key":"e_1_2_10_8_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(17)33095-7"},{"key":"e_1_2_10_9_1","doi-asserted-by":"publisher","DOI":"10.1002\/phar.1889"},{"key":"e_1_2_10_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.02605-12"},{"key":"e_1_2_10_11_1","unstructured":"Sciensano.Epid\u00e9miologie du sida et de l'infection \u00e0 VIH en Belgique: situation au 31 d\u00e9cembre 2020. Accessed September 8 2021.https:\/\/www.sciensano.be\/en\/biblio\/epidemiologie-du-sida-et-de-linfection-a-vih-en-belgique-situation-au-31-decembre-2020"},{"key":"e_1_2_10_12_1","unstructured":"United Nations Statistics Division.Composition of macro geographical (continental) regions geographical sub\u2010regions and selected economic other groupings. Accessed June 22 2021.https:\/\/unstats.un.org\/unsd\/mi\/africa.htm"},{"key":"e_1_2_10_13_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/cix1131"},{"key":"e_1_2_10_14_1","unstructured":"NoeS Ummard\u2010BergerK HillenbrandH et al.12\u2010month outcome of Dolutegravir\/Rilpivirine in virologically suppressed HIV\u2010infected patients:real\u2010world data from the German JUNGLE cohort (poster). Presented at HIV Drug Therapy 2020 October 2020 Virtual."},{"key":"e_1_2_10_15_1","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0164753"},{"key":"e_1_2_10_16_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-017-2311-2"},{"key":"e_1_2_10_17_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dky467"},{"key":"e_1_2_10_18_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000016813"},{"key":"e_1_2_10_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2020.105893"},{"key":"e_1_2_10_20_1","unstructured":"DeschanvresC RaffiF ReynesJ et al.Virologic failure and resistance in dolutegravir\u2010based maintenance dual regimens. (poster). Presented at the Conference on Retroviruses and Opportunistic Infections 2020 March 2020 Boston MA."},{"key":"e_1_2_10_21_1","unstructured":"GagliardiniR LorenziniP Cozzi\u2010LepriA et al.Effect of past virological failure on dolutegravir+lamivudine as maintenance regimen (poster). Presented at the Conference on Retroviruses and Opportunistic Infections 2020 March 2020 Boston MA."},{"key":"e_1_2_10_22_1","unstructured":"DiazA CasadoJL DrondaFet al.Dolutegravir plus rilpivirine in suppressed heavily pre\u2010treated HIV\u2010infected patients [abstract tupdb0 106]. Presented at the 21st International AIDS Conference July 2016 Durban South Africa."},{"key":"e_1_2_10_23_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkm516"},{"key":"e_1_2_10_24_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.293.7.817"},{"key":"e_1_2_10_25_1","doi-asserted-by":"publisher","DOI":"10.1086\/523704"},{"key":"e_1_2_10_26_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis104"},{"key":"e_1_2_10_27_1","doi-asserted-by":"publisher","DOI":"10.1186\/s12879-016-1628-6"},{"key":"e_1_2_10_28_1","doi-asserted-by":"publisher","DOI":"10.1097\/00126334-200110010-00001"},{"key":"e_1_2_10_29_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jinf.2004.11.010"},{"key":"e_1_2_10_30_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.ijantimicag.2019.09.002"},{"key":"e_1_2_10_31_1","unstructured":"MaggioloF ComiL GulminettiR et al.Dolutegravir? Lamivudine in patients with suppressed HIV\u2010RNA: long term virologic and immunologic results of a multicenter cohort (poster). Presented at HIV Drug Therapy Glasgow 2018 October 2018 Glasgow Scotland."},{"key":"e_1_2_10_32_1","unstructured":"BravoJ MartinezO Martinez\u2010AlfaroE et al.Multicenter study to evaluate the effectiveness and safety of dolutegravir and lamivudine dual therapy in real life (poster). Presented at the XI Congreso Nacional GeSIDA December 2019 Toledo Spain."},{"key":"e_1_2_10_33_1","unstructured":"PostelN SchneeweissS WyenC et al.Real\u2010world data from the prospective URBAN cohort study on the use of dolutegravir (DTG)\u00a0+\u00a0lamivudine (3TC) in ART\u2010na\u00efve and pre\u2010treated people living with HIV in Germany (Oral presentation). Presented at HIV Drug Therapy Glasgow2020 October 2020 Virtual."},{"key":"e_1_2_10_34_1","unstructured":"BonijolyT Cabi\u00e9A CheretA et al.Week\u201048 efficacy and safety of dolutegravir + rilpivirine dual therapy as a switch strategy in a real\u2010life cohort study (Oral presentation). Presented at the 16th European AIDS Conference October 2017 Milan Italy."},{"key":"e_1_2_10_35_1","doi-asserted-by":"publisher","DOI":"10.1080\/15284336.2019.1628460"},{"key":"e_1_2_10_36_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2020-054821"},{"key":"e_1_2_10_37_1","doi-asserted-by":"publisher","DOI":"10.21037\/jlpm.2018.01.10"},{"key":"e_1_2_10_38_1","doi-asserted-by":"publisher","DOI":"10.1097\/MD.0000000000003108"},{"key":"e_1_2_10_39_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/civ296"},{"key":"e_1_2_10_40_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000001495"},{"key":"e_1_2_10_41_1","doi-asserted-by":"publisher","DOI":"10.1002\/jia2.25484"},{"key":"e_1_2_10_42_1","doi-asserted-by":"publisher","DOI":"10.1097\/QCO.0000000000000616"},{"key":"e_1_2_10_43_1","unstructured":"RolleC\u2010P BerheM SinghT et al.Feasibility efficacy and safety of dolutegravir\/lamivudine (DTG\/3TC) as a first line regimen in a test and treat setting for newly diagnosed people living with HIV (PLWH): 48 week results of the STAT study (Oral Presentation). Presented at the 11th International AIDS Society Conference on HIV Science; July 2021; Virtual."},{"key":"e_1_2_10_44_1","doi-asserted-by":"publisher","DOI":"10.1089\/aid.2020.0117"},{"issue":"6","key":"e_1_2_10_45_1","first-page":"956","article-title":"No significant changes in body fat mass in virologically suppressed","volume":"34","author":"Ciccullo A","year":"2020","journal-title":"HIV\u2010Positive Patients Switched to Lamivudine\u2010Dolutegravir AIDS"},{"key":"e_1_2_10_46_1","doi-asserted-by":"publisher","DOI":"10.1097\/QAD.0000000000002421"},{"key":"e_1_2_10_47_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofaa195"},{"key":"e_1_2_10_48_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciaa177"},{"key":"e_1_2_10_49_1","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciz999"},{"key":"e_1_2_10_50_1","doi-asserted-by":"publisher","DOI":"10.1097\/COH.0000000000000680"},{"key":"e_1_2_10_51_1","doi-asserted-by":"publisher","DOI":"10.1007\/s15010-018-1227-0"}],"container-title":["HIV Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13373","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1111\/hiv.13373","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/hiv.13373","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,8,22]],"date-time":"2023-08-22T00:18:46Z","timestamp":1692663526000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/hiv.13373"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,8]]},"references-count":50,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2023,3]]}},"alternative-id":["10.1111\/hiv.13373"],"URL":"https:\/\/doi.org\/10.1111\/hiv.13373","archive":["Portico"],"relation":{},"ISSN":["1464-2662","1468-1293"],"issn-type":[{"value":"1464-2662","type":"print"},{"value":"1468-1293","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,8]]},"assertion":[{"value":"2022-02-03","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-07-14","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2022-08-08","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}